Accueil>>Signaling Pathways>> Neuroscience>> COX>>Acemetacin

Acemetacin

Catalog No.GC10454

L'acémétacine (TVX 1322) est un anti-inflammatoire non stéroÏdien et un ester d'acide glycolique de l'indométacine qui est un inhibiteur de la cyclooxygénase.

Products are for research use only. Not for human use. We do not sell to patients.

Acemetacin Chemical Structure

Cas No.: 53164-05-9

Taille Prix Stock Qté
10mM (in 1mL DMSO)
36,00 $US
En stock
50mg
50,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Acemetacin (TVX 1322) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.

Acemetacin (TVX 1322) is a non-steroidal anti-inflammatory drug, used for the treatment of osteoarthritis, rheumatoid arthritis, lower back pain, and relieving post-operative pain. Acemetacin (TVX 1322), a glycolic acid ester of indometacin, acts as a prodrug; in the body, it is metabolized to indometacin, which then acts as an inhibitor of cyclooxygenase, producing the anti-inflammatory effects. An advantage of Acemetacin (TVX 1322) is that it reduces gastric damage when compared to indometacin. From Wikipedia.

References:
[1]. Tavares IA, et al. Non-steroidal anti-inflammatory drugs that cause relatively little gastric damage. J Gastroenterol Hepatol. 1998 Nov;13(S3):S190-S192.

Avis

Review for Acemetacin

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Acemetacin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.